A recent study from Mount Sinai has uncovered alarming levels of per- and polyfluoroalkyl substances (PFAS), commonly referred to as “forever chemicals,” in umbilical cord blood, suggesting that fetuses are exposed to a wider array of these harmful compounds than previously understood. The research, which analysed 120 umbilical cord blood samples, identified 42 different PFAS compounds, reinforcing concerns regarding their potential health impacts.
Understanding the Research
Traditionally, testing of umbilical cord blood has been restricted to a limited set of common PFAS compounds, such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS). However, the new study employed a comprehensive “non-targeted analysis” that significantly broadened the scope of detection. Shelly Liu, an associate professor at the Icahn School of Medicine at Mount Sinai and co-author of the study, emphasises that this expanded analysis revealed that “babies are exposed to many more PFAS than we previously thought.”
The study’s findings are particularly concerning considering that PFAS are synthetic chemicals often used to impart water, stain, and grease resistance to a wide range of consumer products. Their persistence in the environment, due to their inability to break down naturally, has led to their classification as “forever chemicals.”
Health Implications for Newborns
The implications of this study are far-reaching. A comprehensive review of existing literature spanning 40 studies found that PFAS have been detected in 30,000 umbilical cord blood samples, underscoring the widespread exposure of fetuses. Elevated levels of PFAS in maternal blood have already been associated with increased risks of infant mortality, low birth weight, and obesity later in life. Furthermore, fetal exposure is linked to long-term health issues, including cancer, neurological disorders, and cardiovascular diseases.
While the Mount Sinai study did not directly assess health outcomes related to the newly discovered PFAS levels, it does raise critical questions about potential risks. Higher concentrations of these chemicals in blood are generally correlated with adverse health effects, and this research highlights the urgent need for more robust regulatory oversight.
Regulatory Failures and Future Directions
Currently, regulatory bodies such as the US Environmental Protection Agency (EPA) have been slow to adapt testing methods to account for the multitude of PFAS compounds that have emerged in recent years. For instance, the EPA typically tests water samples for only around 30 to 40 compounds, despite independent studies identifying thousands in various environments. This gap in regulatory measures raises significant concerns about public health and safety, particularly for vulnerable populations such as pregnant women and newborns.
The Mount Sinai study effectively juxtaposes traditional testing methods against the broader non-targeted analysis, revealing that more comprehensive testing is essential. Liu notes that while the EPA has recently certified a blood test capable of detecting 53 PFAS compounds, Mount Sinai’s analysis uncovered 31 compounds not included in the EPA’s assessment. This discrepancy highlights the urgent need for updated regulatory standards that reflect the complexity of PFAS exposure.
Why it Matters
The findings from this Mount Sinai study serve as a stark reminder of the health risks associated with PFAS exposure, particularly for newborns. As our understanding evolves, it becomes increasingly clear that the true extent of PFAS contamination in human blood has been underestimated due to inadequate measurement techniques. This situation underscores the critical need for enhanced health-protective regulations to prevent future generations from being born polluted with these harmful chemicals. Without immediate action, the potential long-term health consequences for children could be profound, emphasising the necessity for urgent reform in both testing and regulatory frameworks.
